Impres Medical adds $2 million in funding to treat menorrhagia

MINNETONKA, Minnesota — Impres Medical has raised $2 million through convertible debt and other securities to continue work on a device to stop abnormal uterine bleeding, according to a filing with the Securities and Exchange Commission.

Impres’ device goes into the bottom of the uterus and deactivates the patient’s menstrual period. Impres and its investors state the device is minimally invasive and can be used in a doctor’s office. It’s specifically focused on women who won’t have any more children and works as an alternative to hysterectomy or endometrial ablation, a process that which destroys the lining of the womb.

The Minnetonka-based company states its device is being tested in clinical feasibility trials. It raised the $2 million last month, according to the SEC.

Since 2002, the company has raised more than $12 million from firms including WavePoint Investors and Portage Equity.